CARM vs. CTSO, XGN, AWH, LFVN, ADVM, PRLD, GBIO, RENB, OMER, and PBYI
Should you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Cytosorbents (CTSO), Exagen (XGN), Aspira Women's Health (AWH), LifeVantage (LFVN), Adverum Biotechnologies (ADVM), Prelude Therapeutics (PRLD), Generation Bio (GBIO), Renovaro (RENB), Omeros (OMER), and Puma Biotechnology (PBYI). These companies are all part of the "medical" sector.
Cytosorbents (NASDAQ:CTSO) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk, analyst recommendations and community ranking.
Cytosorbents received 424 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Carisma Therapeutics an outperform vote while only 79.13% of users gave Cytosorbents an outperform vote.
In the previous week, Cytosorbents and Cytosorbents both had 4 articles in the media. Cytosorbents' average media sentiment score of 1.59 beat Carisma Therapeutics' score of 0.75 indicating that Carisma Therapeutics is being referred to more favorably in the news media.
32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 6.6% of Cytosorbents shares are owned by company insiders. Comparatively, 17.0% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Cytosorbents has higher revenue and earnings than Carisma Therapeutics. Cytosorbents is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cytosorbents has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
Cytosorbents presently has a consensus price target of $2.00, indicating a potential upside of 127.27%. Carisma Therapeutics has a consensus price target of $8.60, indicating a potential upside of 561.54%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Cytosorbents.
Cytosorbents has a net margin of -75.07% compared to Cytosorbents' net margin of -538.81%. Carisma Therapeutics' return on equity of -129.89% beat Cytosorbents' return on equity.
Summary
Carisma Therapeutics beats Cytosorbents on 10 of the 17 factors compared between the two stocks.
Get Carisma Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Carisma Therapeutics Competitors List
Related Companies and Tools
